Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Werewolf Therapeutics ( (HOWL) ) is now available.
On February 4, 2026, Werewolf Therapeutics, Inc. disclosed that it had received a Nasdaq deficiency notice after its common stock traded below the $1.00 minimum bid price for 30 consecutive business days, putting its Nasdaq Global Select Market listing at risk. The notice does not immediately affect trading, but the company now has 180 days, until August 3, 2026, to bring its share price back above $1.00 for at least 10 consecutive business days, and may seek an additional 180-day compliance period via transfer to the Nasdaq Capital Market; failure to regain compliance could ultimately lead to delisting, though the stock would remain listed during any appeal, while the company monitors its share price and evaluates options to cure the deficiency.
The most recent analyst rating on (HOWL) stock is a Sell with a $0.61 price target. To see the full list of analyst forecasts on Werewolf Therapeutics stock, see the HOWL Stock Forecast page.
Spark’s Take on HOWL Stock
According to Spark, TipRanks’ AI Analyst, HOWL is a Neutral.
The score is held down primarily by weak financial performance (large ongoing losses and cash burn with funding/dilution risk) and bearish technicals (downtrend across major moving averages with negative MACD). Positive pipeline progress and FDA-related updates provide some offset, but loss-making status and lack of dividend support keep the valuation component weak.
To see Spark’s full report on HOWL stock, click here.
More about Werewolf Therapeutics
Average Trading Volume: 642,582
Technical Sentiment Signal: Sell
Current Market Cap: $31.15M
For a thorough assessment of HOWL stock, go to TipRanks’ Stock Analysis page.